Ben Auspitz is the founder of Idrx. Idrx has raised $122M in total funding. Latest round: Series A. Based in Boston, Massachusetts.
Ben Auspitz is a Managing Partner at Curie.Bio, where he is responsible for the Breakout Fund, which focuses on scaling seed-stage companies and identifying external investment opportunities. Prior to Curie.Bio, he co-founded and served as CEO and later chairman of IDRx, a precision oncology company. He also co-founded Forge Life Science Partners, a venture capital fund, and was a Partner at F-Prime Capital for over a decade, focusing on company formation and Series A investing. Auspitz has been involved in founding or funding over 20 companies, leading to eight approved drugs.
Full founder directory · Investor directory · Company funding database · Fundraising library